Bone morphogenetic proteins and the synovial joints

2004 ◽  
pp. 187-212
Author(s):  
Frank P. Luyten ◽  
Rik Lories ◽  
Dirk De Valck ◽  
Cosimo De Bari ◽  
Francesco Dell’Accio
Keyword(s):  
Bone Morphogenetic Proteins ◽  
Synovial Joints

Bone morphogenetic proteins in the development and healing of synovial joints

2001 ◽  
Vol 31 (1) ◽  
pp. 33-42 ◽  
Author(s):  
Christopher J. Edwards ◽  
Philippa H. Francis-West
Keyword(s):  
Bone Morphogenetic Proteins ◽  
Synovial Joints

Bone morphogenetic proteins and the synovial joints

2002 ◽  
pp. 223-248 ◽  
Author(s):  
Frank P. Luyten ◽  
Rik Lories ◽  
Dirk De Valck ◽  
Cosimo De Bari ◽  
Francesco Dell’Accio
Keyword(s):  
Bone Morphogenetic Proteins ◽  
Synovial Joints

592: Loss of Expression of Bone Morphogenetic Proteins Receptor Type II in Prostate Cancer Patients

2004 ◽  
Vol 171 (4S) ◽  
pp. 157-157
Author(s):  
Isaac Y. Kim ◽  
Hanjong Ahn ◽  
Dong Hyeon Lee ◽  
Ronald A. Morton ◽  
Seong Jin Kim
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Bone Morphogenetic Proteins ◽  
Receptor Type ◽  
Type Ii

scholarly journals Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance

2017 ◽  
Vol 24 (10) ◽  
pp. R349-R366 ◽  
Author(s):  
Catherine Zabkiewicz ◽  
Jeyna Resaul ◽  
Rachel Hargest ◽  
Wen Guo Jiang ◽  
Lin Ye
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Bone Morphogenetic Proteins ◽  
Therapeutic Potential ◽  
Current Knowledge ◽  
Breast Tumour ◽  
Cellular Functions ◽  
Foetal Development ◽  
Key Factor ◽  
The Right

Bone morphogenetic proteins (BMPs) belong to the TGF-β super family, and are essential for the regulation of foetal development, tissue differentiation and homeostasis and a multitude of cellular functions. Naturally, this has led to the exploration of aberrance in this highly regulated system as a key factor in tumourigenesis. Originally identified for their role in osteogenesis and bone turnover, attention has been turned to the potential role of BMPs in tumour metastases to, and progression within, the bone niche. This is particularly pertinent to breast cancer, which commonly metastasises to bone, and in which studies have revealed aberrations of both BMP expression and signalling, which correlate clinically with breast cancer progression. Ultimately a BMP profile could provide new prognostic disease markers. As the evidence suggests a role for BMPs in regulating breast tumour cellular function, in particular interactions with tumour stroma and the bone metastatic microenvironment, there may be novel therapeutic potential in targeting BMP signalling in breast cancer. This review provides an update on the current knowledge of BMP abnormalities and their implication in the development and progression of breast cancer, particularly in the disease-specific bone metastasis.

scholarly journals A Model System of the Dynamic Loading Occurring in Synovial Joints: The Biological Effect of Plowing on Pristine Cartilage

2014 ◽  
Vol 199 (5-6) ◽  
pp. 364-372 ◽  
Author(s):  
M. Rita Correro-Shahgaldian ◽  
Chafik Ghayor ◽  
Nicholas D. Spencer ◽  
Franz E. Weber ◽  
Luigi M. Gallo
Keyword(s):  
Dynamic Loading ◽  
Biological Effect ◽  
Model System ◽  
Synovial Joints

scholarly journals Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches

Antioxidants ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 680
Author(s):  
Sung-Woon On ◽  
Seoung-Won Cho ◽  
Soo-Hwan Byun ◽  
Byoung-Eun Yang
Keyword(s):  
Bone Morphogenetic Proteins ◽  
Maxillofacial Surgery ◽  
Treatment Protocol ◽  
Osteonecrosis Of The Jaw ◽  
Therapeutic Modality ◽  
Definitive Treatment ◽  
Antiangiogenic Agents ◽  
Platelet Concentrates ◽  
Therapeutic Approaches ◽  
Positive Effect

Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive and antiangiogenic agents is known to be the leading cause. However, the exact pathogenesis of MRONJ has not been established, and various hypotheses have been proposed, such as oxidative stress-related theory. As a result, a definitive treatment protocol for MRONJ has not been identified, while various therapeutic approaches are applied to manage patients with MRONJ. Although the surgical approach to treat osteomyelitis of the jaw has been proven to be most effective, there are limitations, such as recurrence and delayed healing. Many studies and clinical trials are being conducted to develop another effective therapeutic modality. The use of some materials, including platelet concentrates and bone morphogenetic proteins, showed a positive effect on MRONJ. Among them, teriparatide is currently the most promising material, and it has shown encouraging results when applied to patients with MRONJ. Furthermore, cell therapy using mesenchymal stem cells showed promising results, and it can be the new therapeutic approach for the treatment of MRONJ. This review presents various treatment methods for MRONJ and their limitations while investigating newly developed and researched molecular and cellular therapeutic approaches along with a literature review.

scholarly journals The Role of BMP Signaling in Osteoclast Regulation

2021 ◽  
Vol 9 (3) ◽  
pp. 24
Author(s):  
Brian Heubel ◽  
Anja Nohe
Keyword(s):  
Bone Formation ◽  
Bone Morphogenetic Proteins ◽  
Bone Diseases ◽  
Bmp Signaling ◽  
Bone Homeostasis ◽  
Direct Stimulation ◽  
Federal Drug Administration ◽  
Bmp Pathway ◽  
Stimulation Of

The osteogenic effects of Bone Morphogenetic Proteins (BMPs) were delineated in 1965 when Urist et al. showed that BMPs could induce ectopic bone formation. In subsequent decades, the effects of BMPs on bone formation and maintenance were established. BMPs induce proliferation in osteoprogenitor cells and increase mineralization activity in osteoblasts. The role of BMPs in bone homeostasis and repair led to the approval of BMP2 by the Federal Drug Administration (FDA) for anterior lumbar interbody fusion (ALIF) to increase the bone formation in the treated area. However, the use of BMP2 for treatment of degenerative bone diseases such as osteoporosis is still uncertain as patients treated with BMP2 results in the stimulation of not only osteoblast mineralization, but also osteoclast absorption, leading to early bone graft subsidence. The increase in absorption activity is the result of direct stimulation of osteoclasts by BMP2 working synergistically with the RANK signaling pathway. The dual effect of BMPs on bone resorption and mineralization highlights the essential role of BMP-signaling in bone homeostasis, making it a putative therapeutic target for diseases like osteoporosis. Before the BMP pathway can be utilized in the treatment of osteoporosis a better understanding of how BMP-signaling regulates osteoclasts must be established.

Sign in / Sign up

Export Citation Format

Share Document